Ravi S. Mani , Dr. Nikhil Inamdar , Dr. Syed Jafri, Dr. Sezen Altug , Dr. Manish Rungta and Dr. Naveen Surapaneni . Dr. Lee obtained his medical degree from Baylor College of Medicine in Houston and completeda residency in Internal Medicine at the University of Texas Medical Branch in Galveston, before entering his fellowship programs in Galveston and Advanced training in San Antonio, Texas.He has native fluency in Spanish. Dr. Lee and his gastroenterology colleagues are part of Bay Area Gastroenterology in Clear Lake, which was the first Houston gastroenterology and endoscopy practice to offer office-based accredited Virtual colonoscopy screening .Specializing in the diagnosis and treatment of ailments of the stomach, intestines, colon, liver, gallbladder and pancreas, the group has offices in Clear Lake, Houston and Pearland. The group also offers virtual colonoscopy onsite at their accredited Imaging Center, in addition to onsite endoscopic procedures, colonoscopy and upper endoscopy at the Bay Area Houston Endoscopy Center.
Mauna Kea Technologies Announces Strong Presence at Asia-Pacific Digestive Week / World Congress of Gastroenterology 2013
In China, like in the rest of world, gastroenterologists are now given the possibility to improve some of the most important procedures for their patients, thanks to Optical Biopsy. There is also clear evidence that only a short learning curve is required to interpret Optical Biopsy images and use it in routine, said Dr. Marc Giovannini, Chief of Endoscopy at Institut Paoli-Calmettes in Marseilles, France. Dr. Giovannini will be conducting a live procedure with Cellvizio at Changhai Hospital, The Second Military Medical University, Shanghai, in a session organized by Pr. Zhao-Shen Li, Chief of Gastroenterology at Changhai Hospital. Pr. Li is also President of the Chinese Society of Digestive Endoscopy (CSDE) and Vice President of Shanghai Chinese Society of Gastroenterology (CSGE). The very strong exposure enjoyed by Cellvizio at APDW 2013, with 13 presentations confirming the clinical value of Optical Biopsy in gastroenterology represents a key milestone in Asia-Pacific. Our presence reflects the increasing penetration of Optical Biopsy in this region, strengthened by our expanded physical representation in Asian countries, said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies. There is mounting evidence that Cellvizio is having an impact on how physicians in China are treating their patients and there is a fast-growing population that demands access to cutting-edge healthcare. The full schedule of Cellvizio optical biopsy presentations and events at APDW 2013 can be downloaded here About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio’s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S.